Phase 2 Leukaemia Trial, Recruiting NCT06451861 Sponsor: Guangdong Provincial People's Hospital Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06451861
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of blood cancer called AML (Acute Myeloid Leukemia, but not a subtype called APL), based on the 2022 WHO diagnostic standards, and who have not yet received major anti-leukemia treatment (some limited pre-treatments to reduce cell counts may be acceptable)
  • People aged 18 or older
  • People whose general health and ability to function falls within a certain range, as measured by a standard medical scoring system called the ECOG scale (score of 4 or below) (confirm with trial site)
  • Women who are able to become pregnant and agree to use effective contraception during treatment and for at least 3 months after treatment ends, and all participants must sign a consent form agreeing to take part

Who may not be able to join:

  • People with a known allergy to the study drugs being tested
  • People whose leukemia has already stopped responding to the drugs azacitidine or venetoclax
  • People who are unable to swallow and take oral (by mouth) medications
  • People who have an active infection (bacterial, fungal, or viral) that is not under control
  • People who have serious problems with major organs that are not under control, such as heart failure, severe liver failure, or moderate to severe kidney failure
  • People who are already taking part in another clinical trial that could interfere with this one, or anyone the medical team considers unsuitable for participation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jianyu Weng, Guangdong Provincial People Hosptial

Phone: 020-83827812

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Guangdong Provincial People's Hospital
Registry
ClinicalTrials.gov
Start date
21 August 2024
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Composite complete remission (CRc)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov